The combination regimen of paclitaxel (Taxol) and cisplatin (Platinol) for non–small-cell lung cancer has shown improved response rates in some phase II trials, and because of its safety profile, it could offer patients with this
M. Tonato, MD
Advertisement
Articles by M. Tonato, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD
2
Mitomycin Administration via Nephrostomy Tube Enhances Nursing Competency
3
Identifying Psychoneurological Symptom Clusters in Heme Malignancies
4
Overcoming Knowledge Barriers to Accessing Oncology Yoga Programs
5